Warnings Page: Estrogen/Progestin Study,
Nolvadex and Zonegran Updates
August 1, 2002
Study of Estrogen Plus Progestin Halted Due to Increased Risk of Breast Cancer
WASHINGTON, D.C.-The National Heart, Lung and Blood Institute (NHLBI) decided to end a clinical trial focused on the overall benefits and risks of estrogen plus progestin after finding a significant increase in the risk of breast cancer, heart attack and pulmonary embolism among those taking the treatment.
The estrogen plus progestin trial, a component of the Women's Health Initiative (WHI), consisted of 16,608 women ages 50 to 79. The study was designed to evaluate the effects of estrogen plus progestin therapy in the prevention of heart …
UPCOMING CONFERENCES
HarrisMartin’s Artificial Stone Silicosis Epidemic Litigation Conference
January 10, 2025 - Long Beach, CA
The Westin Long Beach
HarrisMartin's New Jersey Asbestos Litigation Conference
February 27, 2025 - New Brunswick, NJ
Hyatt Regency New Brunswick